Publication: Systemic treatment for advanced pancreatic cancer
2
0
Issued Date
2023
Resource Type
File Type
application/pdf
Rights Holder(s)
Scopus
Bibliographic Citation
World Journal of Gastrointestinal Oncology. Vol 15, No.10 (2023), p.1691-1705
Suggested Citation
Leowattana W., Leowattana P., Leowattana T. Systemic treatment for advanced pancreatic cancer. World Journal of Gastrointestinal Oncology. Vol 15, No.10 (2023), p.1691-1705. doi:10.4251/wjgo.v15.i10.1691 Retrieved from: https://hdl.handle.net/20.500.14740/12615
Author(s)
Other Contributor(s)
Abstract
Pancreatic cancer is a deadly disease with an extremely poor 5-year survival rate due to treatment resistance and late-stage detection. Despite numerous years of research and pharmaceutical development, these figures have not changed. Treatment options for advanced pancreatic cancer are still limited. This illness is typically detected at a late stage, making curative surgical resection impossible. Chemotherapy is the most commonly utilized technique for treating advanced pancreatic cancer but has poor efficacy. Targeted therapy and immunotherapy have made significant progress in many other cancer types and have been proven to have extremely promising possibilities; these therapies also hold promise for pancreatic cancer. There is an urgent need for research into targeted treatment, immunotherapy, and cancer vaccines. In this review, we emphasize the foundational findings that have fueled the therapeutic strategy for advanced pancreatic cancer. We also address current advancements in targeted therapy, immunotherapy, and cancer vaccines, all of which continue to improve the clinical outcome of advanced pancreatic cancer. We believe that clinical translation of these novel treatments will improve the low survival rate of this deadly disease. © The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.